Healthcare Finance News March 20, 2025
A substantial price reduction would be needed to make the medications more cost effective, the report finds.
Weight loss drugs such as Wegovy and Zepbound are clinically effective but not cost effective at their current prices, according to a study published in JAMA Health Forum.
Tirzepatide and semaglutide, the generic names for the medications, generate improvements in quality-adjusted life expectancy when they’re paired with lifestyle modification, according to the study. But neither medication was cost effective at the $100,000/quality-adjusted life-year (QALY) benchmark due to their high lifetime treatment costs.
The threshold analysis indicates that a substantial price reduction (30.5% for tirzepatide and 81.9% for semaglutide) would be needed to make the medications more cost effective.
WHAT’S THE IMPACT
Most state...
Today's Sponsors
Today's Sponsor